ARTICLE | Company News

Gilead, WHO infectious news

December 19, 2011 8:00 AM UTC

Gilead will donate 445,000 vials of antifungal drug AmBisome amphotericin B over five years to help WHO treat more than 50,000 patients with visceral leishmaniasis. The biotech already offers AmBisome in a number of countries through its Gilead Access Program. Under the program, Gilead provides AmBisome at no-profit pricing or pricing that is at or below Gilead's manufacturing cost. If sold at the no-profit price, Gilead said the donation would be valued at more than $8 million. ...